CheckMate 025 trial results: Nivolumab versus everolimus in pre-treated advanced kidney cancer

Share :
Published: 26 Sep 2015
Views: 4540
Rating:
Save
Prof Padmanee Sharma - MD Anderson Cancer Center, Houston, USA

Prof Padmanee Sharma presents data from the CheckMate 025 trial at a press conference at ECC 2015

This open-label, phase III trial compared the PD-1 checkpoint inhibitor nivolumab against everolimus in the treatment of patients with metastatic renal cell carcinoma (mRCC).

Nivolumab significantly prolonged the primary endpoint of overall survival in patients whose disease has progressed after their first treatment. This is the only phase III trial to demonstrate such a survival advantage in previously treated mRCC versus standard therapy.

Read the news story here or watch the interview here.

See also comment from Martine Prof Piccart Jules Bordet Institute, Brussels, Belgium).